CLSD Valuation

Clearside Biomedical Inc

Add to Watchlist

Advanced Chart

0.403

-0.005(-1.227%)1D

Overview
Forecast
Valuation
Earnings

CLSD Relative Valuation

CLSD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLSD is overvalued; if below, it's undervalued.

Historical Valuation

Clearside Biomedical Inc (CLSD) is now in the Fair zone, suggesting that its current forward PS ratio of 58.03 is considered Fairly compared with the five-year average of -11.44. The fair price of Clearside Biomedical Inc (CLSD) is between 0.37 to 1.01 according to relative valuation methord.

Relative Value

Fair Zone

0.37-1.01

Current Price：0.41

Fair

-1.94

Trailing

Forward

0.00

EV/EBITDA

Clearside Biomedical Inc. (CLSD) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.30. The thresholds are as follows: Strongly Undervalued below -1.82, Undervalued between -1.82 and -0.76, Fairly Valued between 1.36 and -0.76, Overvalued between 1.36 and 2.43, and Strongly Overvalued above 2.43. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-3.89

EV/EBIT

Clearside Biomedical Inc. (CLSD) has a current EV/EBIT of -3.89. The 5-year average EV/EBIT is -0.25. The thresholds are as follows: Strongly Undervalued below -54.41, Undervalued between -54.41 and -27.33, Fairly Valued between 26.83 and -27.33, Overvalued between 26.83 and 53.91, and Strongly Overvalued above 53.91. The current Forward EV/EBIT of -3.89 falls within the Historic Trend Line -Fairly Valued range.

54.77

Clearside Biomedical Inc. (CLSD) has a current PS of 54.77. The 5-year average PS is 108.27. The thresholds are as follows: Strongly Undervalued below -123.76, Undervalued between -123.76 and -7.74, Fairly Valued between 224.29 and -7.74, Overvalued between 224.29 and 340.31, and Strongly Overvalued above 340.31. The current Forward PS of 54.77 falls within the Historic Trend Line -Fairly Valued range.

-0.86

P/OCF

Clearside Biomedical Inc. (CLSD) has a current P/OCF of -0.86. The 5-year average P/OCF is -5.03. The thresholds are as follows: Strongly Undervalued below -23.44, Undervalued between -23.44 and -14.23, Fairly Valued between 4.18 and -14.23, Overvalued between 4.18 and 13.39, and Strongly Overvalued above 13.39. The current Forward P/OCF of -0.86 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Clearside Biomedical Inc. (CLSD) has a current P/FCF of 0.00. The 5-year average P/FCF is 26.41. The thresholds are as follows: Strongly Undervalued below -105.21, Undervalued between -105.21 and -39.40, Fairly Valued between 92.22 and -39.40, Overvalued between 92.22 and 158.03, and Strongly Overvalued above 158.03. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Clearside Biomedical Inc (CLSD) has a current Price-to-Book (P/B) ratio of -0.65. Compared to its 3-year average P/B ratio of 0.16 , the current P/B ratio is approximately -507.21% higher. Relative to its 5-year average P/B ratio of 4.45, the current P/B ratio is about -114.55% higher. Clearside Biomedical Inc (CLSD) has a Forward Free Cash Flow (FCF) yield of approximately -66.49%. Compared to its 3-year average FCF yield of -26.12%, the current FCF yield is approximately 154.55% lower. Relative to its 5-year average FCF yield of -18.40% , the current FCF yield is about 261.29% lower.

-0.66

P/B

Median3y

0.16

Median5y

4.45

-70.44

FCF Yield

Median3y

-26.12

Median5y

-18.40

Competitors Valuation Multiple

The average P/S ratio for CLSD's competitors is 38.87, providing a benchmark for relative valuation. Clearside Biomedical Inc Corp (CLSD) exhibits a P/S ratio of 58.03, which is 49.29% above the industry average. Given its robust revenue growth of 446.67%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CLSD.O

Clearside Biomedical Inc

Onkure Therapeutics Inc

Performance Decomposition

Market capitalization of CLSD decreased by 60.10% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 90.00K to 492.00K.

The secondary factor is the Margin Expansion, contributed -89.17%to the performance.

Overall, the performance of CLSD in the past 1 year is driven by Revenue Growth. Which is more sustainable.

446.67%

90.00K → 492.00K

Revenue Growth

-89.17%

-8.44K → -913.62

Margin Expansion

-417.60%

0.35 → -1.12

P/E Change

-60.10%